 Home > Medical News > Latest Medical News > Euho Pharma's global multicenter Phase I clinical study of YH002 (OX40 antibody) combined with YH001 (CTLA-4 antibody) completed the first patient dosing

Euho Pharma's global multicenter Phase I clinical study of YH002 (OX40 antibody) combined with YH001 (CTLA-4 antibody) completed the first patient dosing

 Last Update: 2022-04-30
 Source: Internet
 Author: User

Tags

innate immune cells

anti infection drugs

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

BEIJING, March 8, 2022 /PRNewswire/ -- Euho Pharma, a wholly-owned subsidiary of Biositu, today announced an international multi-center ( MRCT) Phase I clinical study (No.

This study is an open-label, phase I dose escalation study of YH002 mAb combined with YH001 mAb in patients with advanced solid tumors

Prior to this, Yoho Pharma had completed the single-dose escalation studies of YH001 and YH002, respectively, and the results showed that YH001 and YH002 had good tolerability and safety

In this regard, Dr.

About YH002

YH002 is a recombinant humanized IgG1 monoclonal antibody that specifically targets human tumor necrosis factor receptor superfamily member 4 (TNFRSF4, OX40), thereby inducing pleiotropic downstream anticancer activity

About YH001

YH001 is an anti-CTLA-4 monoclonal antibody that enhances the body's own immune response against tumor cells by enhancing the removal of regulatory T cells (Treg) in the tumor microenvironment, thereby achieving the purpose of treating various tumors

About Euho Pharma

As a wholly-owned subsidiary of Bioset, Euho Pharma undertakes the mission of clinical development for Bioset's R&D pipeline.

About Biositu

Biocytos is an international biopharmaceutical company with innovative technology-driven research and development of new drugs.

Source: Biositu

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.